Discover

Back to filter

Related topics

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles

Spectral Instruments Imaging

Jun 23, 2021

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma....

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jun 21, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in...

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

May 21, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest...

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

May 19, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

May 18, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell...

Show all topics (10)

Preclinical PET imaging in studies of candidate therapeutics

Jun 22, 2017

Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.

Read more

Scientific paper
Application

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Albira combines PET, SPECT and CT imaging in a unique and extremely powerful way

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey